Neuroanatomical abnormalities related to dexamethasone exposure in survivors of childhood acute lymphoblastic leukemia.
Nicholas Steve PhillipsYin Ting CheungJohn O GlassMatthew A ScogginsWei LiuRobert J OggDaniel A MulrooneyChing-Hong PuiLeslie L RobisonWilburn E ReddickMelissa M HudsonKevin R KrullPublished in: Pediatric blood & cancer (2019)
Survivors of childhood acute lymphoblastic leukemia (ALL) treated with chemotherapy only are at risk for neurocognitive impairment. Regions of interest were identified a priori based on glucocorticoid receptor distribution, and sex-stratified multivariable linear regression models were used to test associations between brain MRI morphology and total number of intrathecal injections, and serum concentration of dexamethasone and methotrexate. Compared with controls, ALL survivors have persistently smaller volumes in the bilateral cerebellum (P < 0.005), hippocampal subregions (P < 0.03), temporal lobe regions (P < 0.03), frontal lobe regions (P < 0.04), and parietal lobe regions (precuneus; P < 0.002). Long-term problems with learning may be related to residual posttreatment brain differences.
Keyphrases
- acute lymphoblastic leukemia
- young adults
- high dose
- resting state
- functional connectivity
- allogeneic hematopoietic stem cell transplantation
- low dose
- white matter
- mental health
- magnetic resonance imaging
- working memory
- cerebral ischemia
- computed tomography
- bipolar disorder
- early life
- radiation therapy
- multiple sclerosis
- newly diagnosed
- platelet rich plasma
- binding protein
- chemotherapy induced
- temporal lobe epilepsy